We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00356070
First Posted: July 25, 2006
Last Update Posted: April 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Norwegian University of Science and Technology
  Purpose
The treatment of ADHD in jail will help the prisoners in their rehabilitation process

Condition Intervention
Attention Deficit Hyperactivity Disorder Drug: Strattera

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • The symptoms of Attention Deficit Hyperactive Disorders and the prisoners use of the prisons rehabilitation services before and after treatment will be measured

Estimated Enrollment: 40
Actual Study Start Date: January 2006
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Detailed Description:
Prisoners with ADHD will be offered treatment with Stratera, and we wanted to study their use of the prisons rehabilitation offers as school, programs and work training before and after treatment with Stratera.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All prisoners that fullfill the diagnostic criterias for ADHD -

Exclusion Criteria:

All other prisoners -

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356070


Locations
Norway
St. Olavs Hospital. Departement for forensic psyciatry, Brøset.
Trondheim, Norway, 7040
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Principal Investigator: Roger Almvik, md phd St. Olavs Hospital, Departement of forensic psychiatry, Brøset
  More Information

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00356070     History of Changes
Other Study ID Numbers: AH 4.2005.147
First Submitted: July 24, 2006
First Posted: July 25, 2006
Last Update Posted: April 28, 2017
Last Verified: April 2017

Keywords provided by Norwegian University of Science and Technology:
Attention Deficit Hyperactivity Disorder, treatment,
Strattera,
rehabilitation

Additional relevant MeSH terms:
Disease
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Atomoxetine Hydrochloride
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs